Dr. Pecora on CTLA-4 and PD-1 Combinations in Multiple Myeloma

Video

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the combination of CTLA-4 and PD-1 inhibitors for the treatment of patients with multiple myeloma.

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the combination of CTLA-4 and PD-1 inhibitors for the treatment of patients with multiple myeloma.

The rationale behind this combination is that CTLA-4 inhibitors are a true suppressor of T-regulatory cells. Additionally, CTLA-4 works centrally, whereas PD-1 works in the periphery, which makes this an ideal combination, explains Pecora.

Related Videos
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Related Content
FDA

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024
Article
Paul G. Richardson, MD

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

October 2nd 2023
Podcast
Paul G. Richardson, MD, of Dana-Farber Cancer Institute

Richardson Discusses Implications of the FDA Withdrawal of Melflufen in Multiple Myeloma

April 18th 2024
Article
Ajay K. Nooka, MD, MPH, FACP

FDA Approval Insights: Elranatamab in Relapsed/Refractory Multiple Myeloma

September 21st 2023
Podcast
Sundar Jagannath, MBBS, of Tisch Cancer Institute, Mount Sinai

Linvoseltamab Elicits Deep Responses in Late-Stage R/R Multiple Myeloma

April 8th 2024
Article
The FDA has approved ciltacabtagene autoleucel (Carvykti; cilta-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide (Revlimid).

FDA Approves Cilta-Cel for R/R Multiple Myeloma After at Least One Prior Line of Therapy

April 6th 2024
Article